Therapeutic compositions
This application relates to therapeutic siRNA agents and methods of making and using the agents.
1. An iRNA duplex comprising: a first monomer in a first sequence and a second monomer in a second sequence within the first 3, 4, 5, or 6 positions from either the 3′ end or the 5′ end,
wherein the first and second monomers are selected such that the stability of the pairing of the monomers contributing to forming a duplex between the first and second sequences differs from the stability of the pairing between the first sequence and a target sequence or between the second sequence and a target sequence,
wherein the iRNA duplex has a blunt end at one end of the iRNA duplex and an overhang at the other end of the iRNA duplex, and
wherein the iRNA duplex is represented by
S
5′ R 1 N 1 N 2 N 3 N 4 N 5 [N] N -5 N -4 N -3 N -2 N -1 R 2 3′
AS
3′ R 3 N 1 N 2 N 3 N 4 N 5 [N] N -5 N -4 N -3 N -2 N -1 R 4 5′
S:AS
P 1 P 2 P 3 P 4 P 5 [N] P -5 P -4 P -3 P -2 P -1 5′
wherein:
S represents a sense strand corresponding to the second sequence;
AS represents an antisense strand corresponding to the first sequence;
R 1 is an optional overhang at the 5′-end of the sense strand;
R 2 is an optional overhang at the 3′-end of the sense strand;
R 3 is an optional overhang at the 3′-end of the antisense strand;
R 4 is an optional overhang at the 5′-end of the antisense strand;
N is a monomeric subunit;
indicates the optional presence of additional subunit pairs; and
P x is a pairing of sense N X and antisense N X where x is −5 to 5.
2. The iRNA duplex of claim 1 , wherein one or more pairs in P −5 through P −1 are independently A:U, G:U, I:C, or mismatched pairs.
3. The iRNA duplex of claim 1 , wherein one or more pairs in P −4 through P −1 are G:U pairs.
4. The iRNA duplex of claim 1 , wherein one or more pairs in P −5 through P −1 are A:U pairs.
5. The iRNA duplex of claim 1 , wherein one or more pairs in P −3 through P −1 are A:U pairs.
6. An iRNA duplex comprising: a first monomer in a first sequence and a second monomer in a second sequence within the first 3, 4, 5, or 6 positions from either the 3′ end or the 5′ end,
wherein the first and second monomers are selected such that the stability of the pairing of the monomers contributing to forming a duplex between the first and second sequences differs from the stability of the pairing between the first sequence and a target sequence or between the second sequence and a target sequence,
wherein the iRNA duplex is represented by
S
5′ R 1 N 1 N 2 N 3 N 4 N 5 [N] N -5 N -4 N -3 N -2 N -1 R 2 3′
AS
3′ R 3 N 1 N 2 N 3 N 4 N 5 [N] N -5 N -4 N -3 N -2 N -1 R 4 5′
S:AS
P 1 P 2 P 3 P 4 P 5 [N] P -5 P -4 P -3 P -2 P -1 5′
wherein:
S represents a sense strand corresponding to the second sequence;
AS represents an antisense strand corresponding to the first sequence;
R 1 is an optional overhang at the 5′-end of the sense strand;
R 2 is an optional overhang at the 3′-end of the sense strand;
R 3 is an optional overhang at the 3′-end of the antisense strand;
R 4 is an optional overhang at the 5′-end of the antisense strand;
N is a monomeric subunit;
[N] indicates the optional presence of additional subunit pairs; and
P x is a pairing of sense N x and antisense N x where x is −5 to 5,
wherein the subunit at P −1 of the 5′-end of the antisense strand is A or a modified base which pairs with T, or U or a modified base which pairs with A, and
wherein the subunits at P −1 are the first monomer and second monomer, respectively.
7. The iRNA duplex of claim 1 , wherein one or more pairs in P 5 through P 1 are independently G:C, A:T, A:U, 2-amino-A:U, 2-thio U or 5 Me-thio-U:A, G-clamp:G, guanadinium-G-clamp:G; psuedo uridine:A, or a pair in which one or both subunits has a sugar modification.
8. The iRNA duplex of claim 1 , wherein one or more pairs in P 1 through P 4 , are G:C.
9. The iRNA duplex of claim 1 , wherein one or more pairs in P −5 through P −1 are independently A:U, G:U, I:C, or mismatched pairs, and wherein at least 1 or more pairs in P 5 through P 1 are, independently, G:C, A:T, A:U, 2-amino-A:U, 2-thio U or 5 Me-thio-U:A, G-clamp:G, guanadinium-G-clamp:G; psuedo uridine:A, or a pair in which one or both subunits has a sugar modification.
10. The iRNA duplex of claim 1 , wherein the pairing of the first monomer contributing to a duplex between the first sequence and its target sequence or the pairing of the second monomer contributing to a duplex between the second sequence and its target sequence has a decreased stability.
11. The iRNA duplex of claim 10 , wherein the pairing is mismatch.
12. The iRNA duplex of claim 11 , wherein the mismatch refers to no pairing or is a non-canonical Watson-Crick pairing.
13. The iRNA duplex of claim 12 , wherein the mismatch is a non-canonical Watson-Crick pairing selected from the group consisting of U:U, G:G, G:Atrans, G:Acis, and G:U.
14. The iRNA duplex of claim 1 , wherein the iRNA duplex has a blunt end at the 5′-end of the antisense strand and a two-nucleotide overhang at the 3′-end of the antisense strand.
15. The iRNA duplex of claim 1 , wherein the first and second sequences are each 15-30 nucleotides in length.
16. The iRNA duplex of claim 15 , wherein the first and second sequences are each 19-25 nucleotides in length.
17. The iRNA duplex of claim 1 , wherein one of the first and second sequences is 21 nucleotides in length, and the other is 23 nucleotides in length.
18. The iRNA duplex of claim 6 , wherein the pair at P-i is A:U pair.
19. The iRNA duplex of claim 6 , wherein the iRNA duplex has a blunt end at one end of the iRNA duplex and an overhang at the other end of the iRNA duplex.
20. The iRNA duplex of claim 19 , wherein the iRNA duplex has a blunt end at the 5′-end of the antisense strand and a two-nucleotide overhang at the 3′-end of the antisense strand.